Trevi Therapeutics (NASDAQ:TRVI) Upgraded to Strong-Buy at EF Hutton Acquisition Co. I

EF Hutton Acquisition Co. I upgraded shares of Trevi Therapeutics (NASDAQ:TRVI) to a strong-buy rating in a report issued on Monday, Zacks.com reports.

Several other research analysts have also commented on the company. Needham & Company LLC reissued a buy rating and issued a $8.00 price objective on shares of Trevi Therapeutics in a research report on Wednesday, May 8th. Rodman & Renshaw assumed coverage on Trevi Therapeutics in a report on Thursday, June 13th. They set a buy rating and a $7.00 target price on the stock.

Trevi Therapeutics Stock Performance

Shares of NASDAQ:TRVI opened at $2.97 on Monday. The stock has a 50-day simple moving average of $2.80 and a 200-day simple moving average of $2.77. The stock has a market capitalization of $209.19 million, a P/E ratio of -8.74 and a beta of 1.00. Trevi Therapeutics has a 1 year low of $0.97 and a 1 year high of $4.00.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). During the same period in the prior year, the firm posted ($0.07) EPS. Analysts predict that Trevi Therapeutics will post -0.45 earnings per share for the current year.

Insider Buying and Selling at Trevi Therapeutics

In other news, insider Thomas Sciascia sold 18,660 shares of Trevi Therapeutics stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $2.76, for a total transaction of $51,501.60. Following the sale, the insider now directly owns 220,315 shares of the company’s stock, valued at $608,069.40. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 76,478 shares of company stock valued at $199,349 in the last ninety days. Insiders own 24.37% of the company’s stock.

Institutional Trading of Trevi Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Ally Bridge Group NY LLC bought a new position in Trevi Therapeutics during the 2nd quarter valued at $4,395,000. Opaleye Management Inc. lifted its position in shares of Trevi Therapeutics by 48.6% during the fourth quarter. Opaleye Management Inc. now owns 2,535,000 shares of the company’s stock worth $3,397,000 after purchasing an additional 829,100 shares during the last quarter. Logos Global Management LP grew its stake in Trevi Therapeutics by 27.3% in the second quarter. Logos Global Management LP now owns 2,800,000 shares of the company’s stock worth $8,344,000 after purchasing an additional 600,000 shares in the last quarter. Frazier Life Sciences Management L.P. increased its holdings in Trevi Therapeutics by 7.3% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 7,381,090 shares of the company’s stock valued at $9,891,000 after buying an additional 500,000 shares during the last quarter. Finally, Rosalind Advisors Inc. raised its stake in Trevi Therapeutics by 50.3% during the second quarter. Rosalind Advisors Inc. now owns 1,391,577 shares of the company’s stock valued at $4,147,000 after buying an additional 465,561 shares in the last quarter. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.